AIMS_logo-small.png

©2018 by AIMS Institute | 2825 Eastlake Ave E, #115, Seattle, WA 98102 | Mon - Fri: 9 am - 7 pm | info@aimsinstitute.net | phone: 206-420-1321 |

fax: 833-584-0067

Research

AIMS Institute conducts IRB-approved prospective clinical outcomes studies to evaluate the safety and effectiveness of our therapy programs.  We ask all of our patients to participate.

 

AIMS Institute is working with the U.S. FDA and DEA towards conducting the first human study of ayahuasca tea therapy in the U.S.

 

Dr. Standish has been principal investigator on numerous clinical studies funded by the National Institutes of Health.

 

Dr. Aggarwal, as a National Science Foundation Graduate Research Fellow, was the principal investigator on the first study with state-authorized medical cannabis patients conducted under NIH-issued federal Certificates of Confidentiality.  His peer-reviewed publications have been cited over 500 times.

 

Dr. Aggarwal and Standish are both experienced physicians and scientists.

Read some of their publications below.

Use of cannabinoids in cancer care: palliative care

S.K. Aggarwal

Current Oncology, March 2016

Breast Cancer Integrative Oncology Care and Its Costs

L.J. Standish et al. 

Integrative Cancer Therapies, March 2017

Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions

S.K. Aggarwal et al. 

Journal of Opioid Management, May/June 2009

Breast Cancer and the Immune System

L.J. Standish et al.

Journal of the Society for Integrative Oncology, Fall 2008

Cannabinoid Integrative Health 101

S.K. Aggarwal 

Huffington Post, April 2016

Trametes versicolor Mushroom Immune Therapy in Breast Cancer

L.J. Standish et al. 

Journal of the Society for Integrative Oncology, Summer 2008